Ozempic & HS: Biomarkers, Evidence & Compounded Alternatives

Last reviewed: May 16, 2026 Last updated: May 16, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ozempic (semaglutide) is not FDA-approved for hidradenitis suppurativa, but emerging clinical interest suggests GLP-1 receptor agonists may help reduce systemic inflammation and potentially improve symptoms in some HS patients. This mechanism is based on GLP-1's anti-inflammatory properties rather than direct skin-targeted action.

Hidradenitis suppurativa is a chronic inflammatory condition affecting apocrine glands, often driven by dysregulated immune responses and metabolic factors. Understanding whether GLP-1 therapy may support HS management requires evaluating individual biomarker patterns, genetic predispositions, and clinical context—not a one-size approach.

What HS Is and Why Inflammation Matters

Hidradenitis suppurativa involves recurrent, painful nodules and abscesses in skin folds. It is driven by follicular occlusion, bacterial colonization, and an overactive innate immune response. TNF-alpha and IL-17 are key inflammatory mediators implicated in HS pathogenesis.

Traditional HS treatments include biologics (TNF-alpha inhibitors, IL-17 inhibitors), antibiotics, and surgical intervention. Researchers are exploring whether systemic anti-inflammatory agents—including GLP-1 agonists—might address underlying inflammatory pathways and reduce flare frequency or severity.

GLP-1 Mechanism and HS: What Clinical Evidence Shows

GLP-1 receptor agonists activate GLP-1 receptors on immune cells and intestinal epithelial cells, reducing pro-inflammatory cytokine production and supporting intestinal barrier integrity. These mechanisms may theoretically benefit inflammatory skin conditions, though dedicated HS trials remain limited.

Evidence Category	Current Status
Dedicated HS RCTs with semaglutide	No large randomized controlled trials published; mostly case reports and observational data
Proposed mechanism in HS	Anti-inflammatory signaling via GLP-1R; potential reduction in TNF-alpha and IL-17
Patient populations studied	Mostly type 2 diabetes or obesity; HS-specific cohorts lacking
Timeline for potential benefit	Typically 8–12 weeks minimum; individual response highly variable

Biomarkers and Genetic Predisposition in HS Management

HS patients often show elevated inflammatory biomarkers including TNF-alpha, C-reactive protein (CRP), and IL-17. describing the pathway-level variants involved.

Genetic variants in GIPR, and other peptide pathway genes can influence how an individual's immune and metabolic systems respond to GLP-1 signaling. Understanding these predispositions may help clinicians and patients have more informed conversations about whether GLP-1 therapy is worth exploring alongside standard HS management.

Who Should Consider GLP-1 for HS: Provider-Guided Eligibility

GLP-1 therapy is not a first-line or approved HS treatment. Candidates may include HS patients with concurrent type 2 diabetes or obesity, elevated inflammatory biomarkers, inadequate response to biologic agents, or those seeking adjunctive anti-inflammatory support. Any consideration requires close provider oversight.

Patients should discuss HS severity, current treatment regimen, comorbidities, side effect tolerance, and whether HS-specific inflammatory biomarkers suggest potential benefit. A provider can assess whether GLP-1 represents a reasonable adjunctive option or whether standard biologics or other therapies remain the priority.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context by revealing predispositions in peptide receptor pathways (GIPR rs1800437, FTO rs9939609) that influence how your body processes GLP-1 signaling and metabolic regulation. This information, combined with clinical biomarker data, can support a more informed conversation with your healthcare provider about whether compounded GLP-1 therapy might complement your HS management plan.

The genetic test does not predict exact medication response or guarantee HS improvement. Rather, it identifies genetic variants linked to variation in peptide pathway function. Interpreting these results with a qualified provider helps contextualize whether your genetic profile aligns with potential benefits of GLP-1 therapy, factoring in your individual inflammatory state and HS severity.

If you are exploring compounded GLP-1 options alongside HS management, PlexusDx can support a more personalized assessment through genetic testing and access to compounded semaglutide or tirzepatide formulations. All recommendations should be made in partnership with your dermatologist or HS specialist to ensure alignment with your overall treatment strategy.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is semaglutide approved for treating hidradenitis suppurativa?

No. The article states plainly that it is not FDA-approved for hidradenitis suppurativa, and that interest in the connection rests on proposed anti-inflammatory mechanisms rather than an approved use. It also says this is not a first-line therapy for the condition. Anything along these lines would be an off-label conversation with a dermatologist or HS specialist, not a self-directed decision.

Which inflammatory signals does the article link to hidradenitis suppurativa?

It names TNF-alpha and IL-17 as key mediators implicated in how the condition develops, alongside follicular occlusion, bacterial colonization and an overactive innate immune response. It adds that patients often show elevated inflammatory markers including TNF-alpha and C-reactive protein. Existing treatments it lists target those same signals through TNF-alpha and IL-17 inhibitors, antibiotics, or surgery.

How could GLP-1 signaling touch inflammation at all?

The article says GLP-1 receptors sit on immune cells and intestinal epithelial cells, not just in the pancreas and brain, so activating them can reduce pro-inflammatory cytokine production and support intestinal barrier integrity. That is a systemic anti-inflammatory route rather than anything acting directly on skin. It presents this as a theoretical basis for interest, not a demonstrated effect on skin disease.

What quality of evidence exists here so far?

Thin, by the article's own account. Its evidence table says no large randomized controlled trials with semaglutide in this condition have been published, leaving mostly case reports and observational data. It adds that the populations studied were largely people with type 2 diabetes or obesity, with condition-specific cohorts lacking. That gap is why it frames the whole discussion as exploratory.

Which patients might a provider consider this for as an add-on?

The article suggests possible candidates include people who also have type 2 diabetes or obesity, those with elevated inflammatory markers, and those whose response to biologic agents has been inadequate or who are seeking additional anti-inflammatory support. It stresses close provider oversight in every case. It also says the conversation should cover disease severity, current regimen, other conditions and tolerance for side effects.

Related Reading

• Alternatives For Ozempic
• Ozempic Alternatives
• Lifemd Ozempic
• Eden Ozempic

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.